Shukra Pharmaceuticals Limited (BOM:524632)
India
· Delayed Price · Currency is INR 41.43
-1.75 (-4.05%)
At close: Mar 6, 2026
Shukra Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 636.73 | 325.87 | 745.73 | 588.34 | 204.86 | 111.96 | Upgrade
|
| Other Revenue | 8.96 | - | - | 6.59 | -0 | - | Upgrade
|
| Revenue | 645.69 | 325.87 | 745.73 | 594.93 | 204.86 | 111.96 | Upgrade
|
| Revenue Growth (YoY) | 93.34% | -56.30% | 25.35% | 190.41% | 82.97% | -5.49% | Upgrade
|
| Cost of Revenue | 118.52 | 82.92 | 445.34 | 454.25 | 105.17 | 27.69 | Upgrade
|
| Gross Profit | 527.17 | 242.95 | 300.39 | 140.68 | 99.69 | 84.27 | Upgrade
|
| Selling, General & Admin | 95.08 | 72.02 | 81.76 | 53.83 | 55.4 | 44.76 | Upgrade
|
| Other Operating Expenses | 42.29 | 16.36 | 2.03 | 21.88 | 14.94 | 21.97 | Upgrade
|
| Operating Expenses | 171.16 | 118.43 | 104.29 | 94.09 | 86.96 | 81.47 | Upgrade
|
| Operating Income | 356.02 | 124.52 | 196.09 | 46.59 | 12.73 | 2.8 | Upgrade
|
| Interest Expense | -10.32 | -5.21 | -2.76 | -2.56 | -2.81 | -0.13 | Upgrade
|
| Interest & Investment Income | 14.79 | 14.79 | 5.59 | 0.64 | 0.31 | 0.47 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.74 | -0.74 | -0.09 | -0.25 | -0.05 | -0.2 | Upgrade
|
| EBT Excluding Unusual Items | 359.75 | 133.37 | 198.83 | 44.42 | 10.18 | 2.93 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -1.95 | Upgrade
|
| Pretax Income | 359.75 | 133.37 | 198.83 | 44.42 | 10.18 | 0.98 | Upgrade
|
| Income Tax Expense | 68.14 | 37.61 | 13.46 | 0.35 | 2.67 | -0.9 | Upgrade
|
| Net Income | 291.61 | 95.75 | 185.37 | 44.07 | 7.51 | 1.88 | Upgrade
|
| Net Income to Common | 291.61 | 95.75 | 185.37 | 44.07 | 7.51 | 1.88 | Upgrade
|
| Net Income Growth | 256.72% | -48.35% | 320.68% | 486.98% | 299.10% | 428.31% | Upgrade
|
| Shares Outstanding (Basic) | 735 | 438 | 438 | 67 | 63 | 63 | Upgrade
|
| Shares Outstanding (Diluted) | 735 | 438 | 438 | 67 | 63 | 63 | Upgrade
|
| Shares Change (YoY) | 68.39% | - | 551.03% | 7.38% | - | 0.02% | Upgrade
|
| EPS (Basic) | 0.40 | 0.22 | 0.42 | 0.66 | 0.12 | 0.03 | Upgrade
|
| EPS (Diluted) | 0.40 | 0.22 | 0.42 | 0.66 | 0.12 | 0.03 | Upgrade
|
| EPS Growth | 111.84% | -48.35% | -35.38% | 446.67% | 299.10% | 428.20% | Upgrade
|
| Free Cash Flow | - | 51.75 | -69.57 | -13.22 | 64.39 | -12.54 | Upgrade
|
| Free Cash Flow Per Share | - | 0.12 | -0.16 | -0.20 | 1.03 | -0.20 | Upgrade
|
| Dividend Per Share | - | 0.010 | 0.100 | 0.013 | 0.013 | - | Upgrade
|
| Dividend Growth | - | -90.00% | 700.00% | - | - | - | Upgrade
|
| Gross Margin | 81.64% | 74.55% | 40.28% | 23.65% | 48.66% | 75.27% | Upgrade
|
| Operating Margin | 55.14% | 38.21% | 26.30% | 7.83% | 6.21% | 2.50% | Upgrade
|
| Profit Margin | 45.16% | 29.38% | 24.86% | 7.41% | 3.66% | 1.68% | Upgrade
|
| Free Cash Flow Margin | - | 15.88% | -9.33% | -2.22% | 31.43% | -11.20% | Upgrade
|
| EBITDA | 393.23 | 154.57 | 216.59 | 64.96 | 29.35 | 17.53 | Upgrade
|
| EBITDA Margin | 60.90% | 47.43% | 29.04% | 10.92% | 14.33% | 15.66% | Upgrade
|
| D&A For EBITDA | 37.21 | 30.05 | 20.5 | 18.38 | 16.62 | 14.74 | Upgrade
|
| EBIT | 356.02 | 124.52 | 196.09 | 46.59 | 12.73 | 2.8 | Upgrade
|
| EBIT Margin | 55.14% | 38.21% | 26.30% | 7.83% | 6.21% | 2.50% | Upgrade
|
| Effective Tax Rate | 18.94% | 28.20% | 6.77% | 0.79% | 26.26% | - | Upgrade
|
| Revenue as Reported | 687.76 | 367.94 | 773.88 | 600.3 | 205.67 | 115.52 | Upgrade
|
| Advertising Expenses | - | 3.63 | 21.21 | 0.1 | 0.09 | 0.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.